Brookline Cap M Weighs in on IceCure Medical Q1 Earnings

IceCure Medical Ltd. (NASDAQ:ICCM) – Research analysts at Brookline Cap M issued their Q1 2026 earnings per share estimates for IceCure Medical in a research report issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver expects that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.28) per share. Brookline Cap M also issued estimates for IceCure Medical’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2030 earnings at $0.22 EPS.

A number of other research firms have also weighed in on ICCM. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Price Performance

Shares of ICCM opened at $0.63 on Thursday. The stock has a market capitalization of $45.99 million, a price-to-earnings ratio of -2.62 and a beta of 0.29. IceCure Medical has a 1 year low of $0.54 and a 1 year high of $1.40. The business’s 50 day simple moving average is $0.62 and its 200-day simple moving average is $0.75.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $1.28 million for the quarter, compared to the consensus estimate of $1.30 million. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%.

Hedge Funds Weigh In On IceCure Medical

A number of large investors have recently bought and sold shares of ICCM. Virtu Financial LLC bought a new position in IceCure Medical in the 4th quarter valued at $39,000. Concurrent Investment Advisors LLC bought a new stake in shares of IceCure Medical during the fourth quarter worth $48,000. Finally, Jane Street Group LLC purchased a new stake in shares of IceCure Medical during the fourth quarter valued at $67,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.